Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mixed Results In AZ's DECLARE-TIMI 58 CV Trial Cloud Implications For Farxiga

Executive Summary

While clarification on mixed DECLARE-TIMI 58 CV top-line data in diabetes patients is awaited at November's AHA meeting AstraZeneca says it is confidently pursuing independent studies of its SGLT-2 inhibitor Farxiga in heart failure and kidney disease patients.

You may also be interested in...



AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.

Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer

AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.

Q3 Pharma Earnings Preview: Novo Nordisk, Shire And Teva

Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.

Topics

Related Companies

UsernamePublicRestriction

Register

SC123889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel